{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:17:43Z","timestamp":1792109863262,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["25010702000"],"award-info":[{"award-number":["25010702000"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573938"],"award-info":[{"award-number":["82573938"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473500"],"award-info":[{"award-number":["82473500"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drup.2026.101414","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:54:59Z","timestamp":1779346499000},"page":"101414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity"],"prefix":"10.1016","volume":"87","author":[{"given":"Shaobo","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoguang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyuan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoji","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xigan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101414_bib1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41575-022-00736-1","article-title":"Therapeutic landscape and future direction of metastatic colorectal cancer","volume":"20","author":"Bando","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drup.2026.101414_bib2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"Jama"},{"key":"10.1016\/j.drup.2026.101414_bib3","first-page":"229","article-title":"GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101414_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215369","article-title":"BRAF-mutated colorectal cancer: clinical and molecular insights","volume":"20","author":"Caputo","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101414_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101414_bib6","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.21.02541","article-title":"BRAF-mutated advanced colorectal cancer: a rapidly changing therapeutic landscape","volume":"40","author":"Ciombor","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101414_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101414_bib8","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1038\/s41591-022-01976-z","article-title":"RNF43 mutations predict response to anti-BRAF\/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer","volume":"28","author":"Elez","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2026.101414_bib9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101414_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101414_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102996","article-title":"Treatment of patients with BRAF(V600E)-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset","volume":"9","author":"Germani","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.drup.2026.101414_bib12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","article-title":"Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines","volume":"32","author":"Grothey","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101414_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF - a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101414_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105597","article-title":"Recent advances in B-RAF inhibitors as anticancer agents","volume":"120","author":"Khan","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.drup.2026.101414_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102541","article-title":"European expert panel consensus on the clinical management of BRAF(V600E)-mutant metastatic colorectal cancer","volume":"115","author":"Martinelli","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101414_bib16","article-title":"Patient-derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy","volume":"9","author":"Mo","year":"2022","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.drup.2026.101414_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102905","article-title":"BRAFV600E mutant metastatic colorectal cancer: current advances in personalized treatment and future perspectives","volume":"134","author":"Napolitano","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101414_bib18","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101414_bib19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101414_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24109073","article-title":"Clinical characterization of targetable mutations (BRAF V600E and KRAS G12C) in advanced colorectal cancer-A nation-wide study","volume":"24","author":"Potocki","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101414_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-086026","article-title":"Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis","volume":"391","author":"Qin","year":"2025","journal-title":"Bmj"},{"key":"10.1016\/j.drup.2026.101414_bib22","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1093\/oncolo\/oyac265","article-title":"BRAF V600E and RNF43 Co-mutations predict patient outcomes with targeted therapies in real-world cases of colorectal cancer","volume":"28","author":"Quintanilha","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2026.101414_bib23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101414_bib24","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/annonc\/mdx401","article-title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","volume":"28","author":"Sanz-Garcia","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101414_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101414_bib26","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101414_bib27","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.22.01420","article-title":"FOLFOXIRI plus cetuximab or bevacizumab as first-line treatment of BRAF(V600E)-mutant metastatic colorectal cancer: the randomized phase II FIRE-4.5 (AIO KRK0116) study","volume":"41","author":"Stintzing","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101414_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101414_bib29","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"van de Wetering","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101414_bib30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.drup.2026.101414_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.stem.2023.05.012","article-title":"Organoid cultures for cancer modeling","volume":"30","author":"Yan","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2026.101414_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2026.101414_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101558","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer","volume":"8","author":"Yoshino","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.drup.2026.101414_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114365","article-title":"Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment","volume":"187","author":"Zhang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drup.2026.101414_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41416-024-02711-w","article-title":"Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab","volume":"131","author":"Zwart","year":"2024","journal-title":"Br. J. Cancer"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:14:40Z","timestamp":1783199680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"alternative-id":["S1368764626000658"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101414","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101414"}}